EMA and FDA Unveil Principles for AI Use in Drug Development

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have jointly released a set of ten common principles aimed at guiding the use of artificial intelligence (AI) in drug development. This initiative comes as biopharma companies increasingly adopt AI technologies, fundamentally changing practices across the entire product life cycle, from drug discovery to clinical testing and market introduction.

The principles, which will inform future regulatory guidance in both the United States and the European Union, emphasize the need for AI to be human-centric and ethically aligned. According to the regulators, the framework provides “broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring.”

Key Principles for AI Implementation

At the forefront of the ten principles is the mandate that AI systems must be designed with a human-centric approach, ensuring alignment with ethical values. Development must incorporate a risk-based strategy that considers the specific context in which the AI will be employed. Furthermore, adherence to existing legal, ethical, technical, scientific, cybersecurity, and regulatory standards is essential.

AI systems should also have a well-defined context of use and require the involvement of multidisciplinary expertise throughout their development. Strict data governance and documentation controls are necessary, particularly concerning privacy and the protection of sensitive information.

Risk-based performance assessments are mandated, including evaluations of human-AI interaction, prior to deployment. Continuous monitoring and periodic re-evaluation will ensure that these systems remain effective over time. In addition, the regulators highlight the importance of clear, accessible communication, stating that AI should provide “contextually relevant information to the intended audience, including users and patients.”

Collaborative Efforts and Industry Trends

The EMA and FDA underscore that realizing the full benefits of AI in drug development will require proactive management of the technology, including risk mitigation strategies. Olivér Várhelyi, European Commissioner for Health and Animal Welfare, commented on the principles, stating, “The guiding principles of good AI practice in drug development are a first step of a renewed EU-US cooperation in the field of novel medical technologies.” He added that these principles exemplify how both regions can collaborate to maintain leadership in global innovation while prioritizing patient safety.

The swift integration of AI in the biopharma sector is evidenced by a surge in partnerships between pharmaceutical companies and AI specialists. Recent announcements include collaborations between Iktos and both Servier and Pierre Fabre, as well as Insilico Medicines teaming up with Servier. Additionally, GSK has formed partnerships with Noetik and Helix, while AstraZeneca has acquired Boston-based Modella AI to enhance its research and development capabilities.

As the industry continues to evolve with AI technologies, the guidelines set forth by the EMA and FDA will play a critical role in shaping the safe and effective use of these innovations in drug development.